Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Relapsed/Refractory Multiple Myeloma
NCT02514668Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2015
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Adverse Events up to 12 months and 1 more. Started Sep 2015; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02514668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514668.